Sanofi has completed its regulatory filing obligations by submitting its 2025 Form 20-F to the U.S. Securities and Exchange Commission and its Document d'Enregistrement Universel to the French Autorité des Marchés Financiers. Both documents contain the company's complete audited financial statements and represent the pharmaceutical firm's comprehensive annual financial reporting in accordance with applicable U.S. and French regulatory requirements.
The filings are now accessible to investors and stakeholders through multiple channels, including Sanofi's corporate website, the SEC's EDGAR database, and the AMF's official disclosures platform. Shareholders and interested parties may also request physical copies of the documents directly from the company.
This dual filing reflects Sanofi's status as an international company with significant operations in both the United States and Europe, requiring compliance with both American and European securities regulations.